Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
8.42
-0.39 (-4.43%)
Sep 29, 2026, 12:14 PM EDT - Market open
Satellos Bioscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
186.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Alpha Cognition | 15.26M |
| MediWound | 11.86M |
| Adagene | 9.29M |
| Oramed Pharmaceuticals | 2.00M |
| Veraxa Biotech AG | 29.54K |
MSLE News
- 5 days ago - Satellos announces U.S. FDA cleared IND application for forazapadin - TheFly
- 5 days ago - Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - GlobeNewsWire
- 13 days ago - Satellos Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 14 days ago - Satellos to Present at the 31st Annual Congress of the World Muscle Society - GlobeNewsWire
- 19 days ago - Satellos Bioscience Slides: Corporate presentation - Filings
- 19 days ago - Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 20 days ago - Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ... - GuruFocus
- 20 days ago - Satellos Names Forazapadin As INN For Lead DMD Drug Candidate - Nasdaq